[go: up one dir, main page]

PL2773648T3 - Związki farmaceutyczne do zastosowania w terapii zakażenia clostridium difficile - Google Patents

Związki farmaceutyczne do zastosowania w terapii zakażenia clostridium difficile

Info

Publication number
PL2773648T3
PL2773648T3 PL12772882T PL12772882T PL2773648T3 PL 2773648 T3 PL2773648 T3 PL 2773648T3 PL 12772882 T PL12772882 T PL 12772882T PL 12772882 T PL12772882 T PL 12772882T PL 2773648 T3 PL2773648 T3 PL 2773648T3
Authority
PL
Poland
Prior art keywords
therapy
clostridium difficile
pharmaceutical compounds
difficile infection
infection
Prior art date
Application number
PL12772882T
Other languages
English (en)
Inventor
Bastien Castagner
Jean-Christophe Leroux
Mattias IVARSSON
Gisbert Schneider
Anna PRATSINIS
Original Assignee
ETH Zürich
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47022623&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2773648(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ETH Zürich filed Critical ETH Zürich
Publication of PL2773648T3 publication Critical patent/PL2773648T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/661Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A61K31/6615Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/255Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12Antidiarrhoeals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C305/00Esters of sulfuric acids
    • C07C305/20Esters of sulfuric acids having oxygen atoms of sulfate groups bound to carbon atoms of rings other than six-membered aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/06Phosphorus compounds without P—C bonds
    • C07F9/08Esters of oxyacids of phosphorus
    • C07F9/09Esters of phosphoric acids
    • C07F9/093Polyol derivatives esterified at least twice by phosphoric acid groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/06Phosphorus compounds without P—C bonds
    • C07F9/08Esters of oxyacids of phosphorus
    • C07F9/09Esters of phosphoric acids
    • C07F9/117Esters of phosphoric acids with cycloaliphatic alcohols
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00Processes for the preparation of sugar derivatives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20Carbocyclic rings
    • C07H15/207Cyclohexane rings not substituted by nitrogen atoms, e.g. kasugamycins

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Emergency Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
PL12772882T 2011-09-29 2012-09-28 Związki farmaceutyczne do zastosowania w terapii zakażenia clostridium difficile PL2773648T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP11007933 2011-09-29
EP11007935 2011-09-29
EP12772882.2A EP2773648B1 (en) 2011-09-29 2012-09-28 Pharmaceutical compounds for use in the therapy of clostridium difficile infection
PCT/EP2012/004088 WO2013045107A1 (en) 2011-09-29 2012-09-28 Pharmaceutical compounds for use in the therapy of clostridium difficile infection

Publications (1)

Publication Number Publication Date
PL2773648T3 true PL2773648T3 (pl) 2020-03-31

Family

ID=47022623

Family Applications (1)

Application Number Title Priority Date Filing Date
PL12772882T PL2773648T3 (pl) 2011-09-29 2012-09-28 Związki farmaceutyczne do zastosowania w terapii zakażenia clostridium difficile

Country Status (14)

Country Link
US (1) US9358243B2 (pl)
EP (2) EP2773648B1 (pl)
JP (1) JP5766884B2 (pl)
CN (2) CN103958535A (pl)
AU (2) AU2012314932B2 (pl)
BR (1) BR112014007405B1 (pl)
CA (1) CA2849426C (pl)
DK (1) DK2773648T3 (pl)
EA (1) EA024069B1 (pl)
ES (1) ES2727633T3 (pl)
IL (1) IL231698A (pl)
MX (1) MX347723B (pl)
PL (1) PL2773648T3 (pl)
WO (1) WO2013045107A1 (pl)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA96768C2 (uk) * 2006-08-02 2011-12-12 Йоганес Гутенберг-Універсітет Майнц Лікарський засіб від lct-отруєнь
US11707470B2 (en) 2015-12-11 2023-07-25 Eth Zurich Inositol derivatives for use in pathological crystallization
EP3386548B1 (en) * 2015-12-11 2021-03-17 ETH Zürich Inositol derivatives for use in pathological crystallization
US11028112B2 (en) 2015-12-11 2021-06-08 Eth Zurich Inositol derivatives for use in pathological crystallization
PL3386994T3 (pl) * 2015-12-11 2020-05-18 ETH Zürich 4,6-di-(o-tiofosforano)-inozytolo-1,2,3,5-tetra-o-siarczan dla zakażenia c. difficile
CN106474458B (zh) * 2017-01-05 2020-03-24 重庆医科大学 白介素-27在治疗艰难梭菌感染中的应用
AU2019342857A1 (en) * 2018-09-18 2021-03-25 Vifor (International) Ag Calcium oxalate crystallization inhibitors for renal disorders
CA3113377A1 (en) 2018-10-11 2020-04-16 Sanifit Therapeutics S.A. Inositol phosphates for the treatment of ectopic calcification
BR112021014897A2 (pt) 2019-01-30 2021-09-28 Sanifit Therapeutics, S.A. Composto ou um sal farmaceuticamente aceitável do mesmo, e, composição farmacêutica
EP3818983A1 (en) 2019-11-11 2021-05-12 Sanifit Therapeutics S.A. Inositol phosphate compounds for use in treating, inhibiting the progression, or preventing cardiovascular calcification
US20230167140A1 (en) * 2020-04-30 2023-06-01 Shanghai Senhui Medicine Co., Ltd. Inositol derivative and use thereof
IL303032A (en) 2020-11-20 2023-07-01 Vifor Int Ag Inositol hexakisphosphate analogues for treatment of calcification associated kidney diseases
EP4015494A1 (en) 2020-12-15 2022-06-22 Sanifit Therapeutics S.A. Processes for the preparation of soluble salts of inositol phosphates
AU2022214904A1 (en) 2021-01-26 2023-07-06 Vifor (International) Ag Clinical dosing schedule of inositol phosphate oligo(ethylene glycol) compounds
WO2024047037A1 (en) 2022-08-30 2024-03-07 ETH Zürich Compositions for parenteral sustained release delivery of hydrophilic drugs

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5444901A (en) 1977-09-12 1979-04-09 Ricoh Kk Treating liquid for flat printing plate
SE8605063D0 (sv) * 1986-11-26 1986-11-26 Matti Siren Derivatives of cyclohexane
GB8705811D0 (en) * 1987-03-11 1987-04-15 Research Corp Ltd Inositol derivatives
UA96768C2 (uk) * 2006-08-02 2011-12-12 Йоганес Гутенберг-Універсітет Майнц Лікарський засіб від lct-отруєнь
DE102006062250A1 (de) * 2006-12-22 2008-06-26 Roland Saur-Brosch Verwendung einer Zusammensetzung aus Mineralstoffen und/oder Vitaminen und gegebenenfalls acetogenen und/oder butyrogenen Bakterien zur oralen oder rektalen Verabreichung für die Behandlung und Vorbeugung von abdominalen Beschwerden
US8809392B2 (en) * 2008-03-28 2014-08-19 Ecolab Usa Inc. Sulfoperoxycarboxylic acids, their preparation and methods of use as bleaching and antimicrobial agents
WO2010049921A1 (en) 2008-10-31 2010-05-06 Alimentary Health Limited Disaccharides
WO2012138963A1 (en) 2011-04-06 2012-10-11 The Board Of Regents Of The University Of Texas System Inositol hexakisphosphate analogs and uses thereof

Also Published As

Publication number Publication date
ES2727633T3 (es) 2019-10-17
BR112014007405B1 (pt) 2021-07-13
EP2773648A1 (en) 2014-09-10
IL231698A (en) 2017-06-29
CA2849426A1 (en) 2013-04-04
CN103958535A (zh) 2014-07-30
US9358243B2 (en) 2016-06-07
EA024069B1 (ru) 2016-08-31
NZ624189A (en) 2015-05-29
AU2017202419A1 (en) 2017-05-11
CA2849426C (en) 2020-03-24
DK2773648T3 (da) 2019-05-20
AU2012314932B2 (en) 2017-01-19
CN105949234B (zh) 2018-07-10
EP3521294A1 (en) 2019-08-07
JP5766884B2 (ja) 2015-08-19
JP2014532049A (ja) 2014-12-04
WO2013045107A1 (en) 2013-04-04
AU2017202419B2 (en) 2017-08-31
US20140235590A1 (en) 2014-08-21
EP2773648B1 (en) 2019-03-13
EA201490726A1 (ru) 2014-08-29
CN105949234A (zh) 2016-09-21
AU2012314932A1 (en) 2014-05-15
MX2014003771A (es) 2015-03-20
MX347723B (es) 2017-05-10
BR112014007405A2 (pt) 2017-04-04

Similar Documents

Publication Publication Date Title
PL2773648T3 (pl) Związki farmaceutyczne do zastosowania w terapii zakażenia clostridium difficile
HK1206297A1 (en) Pharmaceutical compositions for combination therapy
HK1186737A1 (en) Derivatives of azaindazole or diazaindazole type as medicament
EP2739144A4 (en) COMPOUNDS AND ITS THERAPEUTIC USE
GB201117313D0 (en) Bacterium for use in medicine
HRP20181896T1 (hr) Farmaceutske formulacije
SG10201604667YA (en) Pharmaceutical preparation
SI2691083T1 (sl) Farmacevtski sestavek sitagliptina
HRP20190050T1 (hr) Farmaceutski pripravci za kombinacijsku terapiju
EP2671605A4 (en) NEEDLESS SYRINGE
HK1206292A1 (en) Medicament administration
GB201105298D0 (en) Pharmaceutical preparation
GB2525835B (en) Pharmaceutical agent
PL2723330T3 (pl) Lek kombinowany zawierający środek naczynioskurczowy
EP2701735A4 (en) LIQUID VACCINE COMPOSITIONS
PL2691119T3 (pl) Preparat farmaceutyczny
SG11201402226PA (en) Therapeutic agent for arthrosis
HUP1100245A2 (en) Pharmaceutical composition for the treatment of wounds
GB201104632D0 (en) Use of medicament
GB201108234D0 (en) Pharmaceutical agent
HUE043019T2 (hu) Gyógyszerészeti készítmények kombinációs terápia céljára
GB201110895D0 (en) Therapeutic use
AU2011900519A0 (en) Drug compositions for the treatment of insomnia
GB201106968D0 (en) Compounds for the treatment of clostridium difficile associated disease
GB201106985D0 (en) Compounds for the treatment of clostridium difficile associated disease